NCT01963182View on ClinicalTrials.gov

Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2019

Study Completion Date

December 9, 2019

Conditions

First Line Metastatic Colorectal Cancer

Interventions

DRUG

Irinotecan

Trial Locations (3)

63011

Centre Jean Perrin, Clermont-Ferrand

CHU Estaing, Clermont-Ferrand

63110

Clinique de la Châtaigneraie, Beaumont

All Listed Sponsors

lead

Centre Jean Perrin

OTHER

NCT01963182 - Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter